Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.96 Analyst target: $7.33 Upside: 273.98%
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.